MYC and prostate carcinoma: To address whether MYC can drive mtDNA replication in prostate cancer cells (PC3), we inhibited MYC activity with a potentially novel small molecule inhibitor MYCi975 (73, 74), followed by metabolic labeling with EdU for incorporation into newly synthesized DNA.